Rogers S, Sanders R C, Alpers M P
Papua New Guinea Institute of Medical Research, Tari.
J Trop Med Hyg. 1991 Apr;94(2):88-91.
A small-scale trial was carried out at Tari in the Southern Highlands Province of Papua New Guinea to determine the effectiveness of a standard subcutaneous dose of Edmonston-Zagreb measles vaccine (Institute of Immunology, Zagreb) administered to children at less than 8 months of age. Specific antibody levels were measured before and 7-11 weeks after vaccination using an ELISA system. Paired sera from 41 children vaccinated at 4-7 months of age and from 18 children vaccinated routinely at 8-29 months of age were available for comparison. No child 6 months of age or older had detectable maternal antibodies and all of these seroconverted. Post-vaccination titres in 12 children aged 6-7 months were not significantly different from those in older children and 1 year later, post-vaccination titres were still high. In Papua New Guinea, and perhaps in other developing countries, it may prove appropriate and acceptable to vaccinate with Edmonston-Zagreb measles vaccine at 6 months of age without recourse to augmentation of dose from that currently recommended in older children.
在巴布亚新几内亚南部高地省的塔里进行了一项小规模试验，以确定给8个月龄以下儿童接种标准皮下剂量的埃德蒙斯顿-萨格勒布麻疹疫苗（萨格勒布免疫研究所生产）的效果。使用酶联免疫吸附测定（ELISA）系统在接种疫苗前以及接种后7至11周测量特异性抗体水平。有来自41名4至7个月龄接种疫苗儿童以及18名8至29个月龄常规接种疫苗儿童的配对血清可供比较。6个月龄及以上儿童均未检测到母体抗体，且所有这些儿童都发生了血清转化。12名6至7个月龄儿童接种疫苗后的滴度与年龄较大儿童的滴度无显著差异，并且1年后，接种疫苗后的滴度仍然很高。在巴布亚新几内亚，或许在其他发展中国家，6个月龄时接种埃德蒙斯顿-萨格勒布麻疹疫苗可能被证明是合适且可接受的，而无需增加目前针对年龄较大儿童推荐的剂量。
